Stockscreener 앱 받기
3.47
5.71%
-0.21
시간 외 거래:
3.50
0.03
+0.86%
전일 마감가:
$3.68
열려 있는:
$3.71
하루 거래량:
2.19M
Relative Volume:
1.96
시가총액:
$244.94M
수익:
$20.76M
순이익/손실:
$-132.49M
주가수익비율:
-1.2996
EPS:
-2.67
순현금흐름:
$-108.55M
1주 성능:
-4.41%
1개월 성능:
-3.61%
6개월 성능:
-48.21%
1년 성능:
-43.85%
1일 변동 폭
$3.40
$3.84
1주일 범위
$3.40
$3.84
52주 변동 폭
$3.38
$11.88
C 4 Therapeutics Inc Stock (CCCC) Company Profile
명칭
C 4 Therapeutics Inc
전화
(617) 231-0700
주소
490 ARSENAL WAY, WATERTOWN
CCCC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
3.47 | 244.94M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Equal-Weight |
| 2024-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-13 | 업그레이드 | Stifel | Hold → Buy |
| 2023-02-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-04-28 | 개시 | Credit Suisse | Underperform |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-10 | 개시 | JP Morgan | Overweight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-11-23 | 개시 | BofA Securities | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-30 | 개시 | Stifel | Hold |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-27 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-27 | 개시 | Jefferies | Buy |
모두보기
C 4 Therapeutics Inc 주식(CCCC)의 최신 뉴스
BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Molecular Glue Degrader Market Key Players AnalysisC4 - openPR
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics stock rises on portfolio update (CCCC:NASDAQ) - Seeking Alpha
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology - The Manila Times
C4 Therapeutics progresses with key 2025 clinical trials - Investing.com
C4 Therapeutics Reveals Strong Cancer Drug Pipeline Progress, Sets Key 2025 Milestones - StockTitan
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $10.67 Consensus PT from Brokerages - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics stock plunges to 52-week low of $3.43 - Investing.com India
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
Equities Analysts Issue Forecasts for C4 Therapeutics FY2029 Earnings - MarketBeat
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
C4 Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock Now - MSN
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Up 11.0% in December - MarketBeat
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Why C4 Therapeutics (CCCC) Is One of the Best Biotech Penny Stocks to Invest in Now? - Yahoo Finance
C4 Therapeutics stock hits 52-week low at $3.6 amid market challenges - Investing.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
State Street Corp Sells 188,035 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) - MarketBeat
Brokerages Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target at $10.67 - MarketBeat
C 4 Therapeutics Inc (CCCC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):